Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

Objective. To evaluate health-related quality of life (HRQOL) and corticosteroid use in patients with moderate to severely active SLE enrolled in two international, multicentre, randomized controlled trials of epratuzumab (ALLEVIATE-1 and -2) and a long-term extension study (SL0006). Methods. Ninety...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Rheumatology (Oxford, England) England), 2014-03, Vol.53 (3), p.502-511
Hauptverfasser:	Strand, Vibeke, Petri, Michelle, Kalunian, Kenneth, Gordon, Caroline, Wallace, Daniel J., Hobbs, Kathryn, Kelley, Lexy, Kilgallen, Brian, Wegener, William A., Goldenberg, David M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenal Cortex Hormones - therapeutic use Adult Antibodies, Monoclonal, Humanized - therapeutic use Arthralgia - drug therapy Clinical Science Dose-Response Relationship, Drug Female Humans Internationality Lupus Erythematosus, Systemic - drug therapy Male Middle Aged Pain Measurement Quality of Life Severity of Illness Index Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!